Generic Aloxi launches from Dr. Reddy’s
Dr. Reddy’s Laboratories has introduced its generic Aloxi (palonosetron hydrochloride injection). The drug, which had been previously approved by the Food and Drug Administration, is indicated to treat chemotherapy-induced nausea and vomiting in adults.
Dr. Reddy’s generic Aloxi will be available in 0.25 mg/5 ml dosage strength. It will be packaged in a carton containing one single-dose vial. The drug’s market size is roughly $446 million for the 12 months ended January 2018, according to IQVIA data.
Dr. Reddy’s generic Aloxi will be available in 0.25 mg/5 ml dosage strength. It will be packaged in a carton containing one single-dose vial. The drug’s market size is roughly $446 million for the 12 months ended January 2018, according to IQVIA data.